Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Br J Haematol. 2012 Dec 13;160(4):530–537. doi: 10.1111/bjh.12163

Figure 1. MicroTEC trial schema.

Figure 1

The plasma concentration of tissue factor-bearing microparticles (TFMP) was measured following enrollment. Individuals with higher concentrations of tissue factor-bearing microparticles were randomized 2:1 to enoxaparin 40 mg daily versus observation. Individuals with low tissue factor-bearing microparticles were followed without anticoagulation. Study subjects were scheduled to undergo lower extremity ultrasound on Day 1 and Day 60 to evaluate for an incidental proximal deep vein thrombosis.